IP Library Patent Application 13358450
Patent Application
App. No. 13/358,450

ENHANCED PROTEIN TRANSDUCTION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/358,450
Abstract

Methods of enhanced protein transduction are provided. Aspects of the methods include contacting a cell with a transduction protein, where the transduction protein includes both a protein-of-interest domain and a protein transduction domain, and a nucleic acid transfection agent. Also provided are systems and kits that find use in practicing methods according to embodiments of the invention. The methods, systems and kits find use in a variety of different applications.

Claims (34)

1 . A method of transducing a cell with a protein, the method comprising contacting the cell with:

(a) a transduction protein comprising:

(i) a protein-of-interest (POI) domain; and

(ii) a protein transduction domain (PTD); and

(b) a nucleic acid transfection agent;

under conditions sufficient to transduce the cell with the protein.

2 . The method according to claim 1 , wherein the transduction protein comprises a distinct PTD.

3 . The method according to claim 2 , wherein the distinct PTD comprises from 5 to 100 amino acids.

4 . The method according to claim 3 , wherein the distinct PTD is selected from the group consisting of PTD found in TAT, VP22,antp and poly-arginine.

5 . The method according to claim 1 , wherein the protein comprises a distributed PTD.

6 . The method according to claim 5 , wherein the distributed PTD comprises a basic patch made up of 3 or more non-sequential basic amino acid residues.

7 . The method according to claim 6 , wherein the number percentage of basic amino acid residues in the basic patch is 30 or more.

8 . The method according to claim 1 , wherein the nucleic acid transfection reagent is selected from the group consisting of Xfect™ transfection reagent, Lipofectamine™ LTX transfection reagent, Lipofectamine 2000™ transfection reagent, SiQuest™ transfection reagent, Transit-siQuest™ transfection reagent, Transit-TKO™ transfection reagent, Transit-LTI™ transfection reagent, Transit-Jurkat™ transfection reagent, Transit-2020™ transfection reagent; chloroquine, PEG, and combinations thereof.

9 . The method according to claim 1 , wherein the method further comprises evaluating the cell to determine whether the cell has been transduced with the transduction protein.

10 . The method according to claim 1 , wherein the method is an in vitro method.

11 . A transduction system comprising:

(a) a host cell;

(b) a transduction protein comprising:

(i) a POI domain; and

(ii) a PTD; and

(c) a nucleic acid transfection agent.

12 . The system according to claim 11 , wherein the transduction protein comprises a distinct PTD.

13 . The system according to claim 12 , wherein the distinct PTD comprises from 5 to 100 amino acids.

14 . The system according to claim 13 , wherein the distinct PTD is selected from the group consisting of PTD found in TAT, VP22, antp and poly-arginine.

15 . The system according to claim 11 , wherein the transduction protein comprises a distributed PTD.

16 . The system according to claim 15 , wherein the distributed PTD comprises a basic patch made up of 3 or more non-sequential basic amino acid residues.

17 . The system according to claim 16 , wherein the number percentage of basic amino acid residues in the basic patch is 30 or more.

18 . The system according to claim 11 , wherein the nucleic acid transfection reagent is selected from the group consisting of from the group consisting of Xfect™ transfection reagent, Lipofectamine™ LTX transfection reagent, Lipofectamine 2000™ transfection reagent, SiQuest™ transfection reagent, Transit-siQuest™ transfection reagent, Transit-TKO™ transfection reagent, Transit-LTI™ transfection reagent, Transit-Jurkat™ transfection reagent, Transit-2020™ transfection reagent; chloroquine, PEG, and combinations thereof.

19 . A kit comprising:

(a) at least one of:

(i) a vector comprising an expression cassette comprising a distinct PTD encoding element; and a cloning site; and

(ii) a transduction protein; and

(b) a nucleic acid transfection agent.

20 . The kit according to claim 19 , wherein the nucleic acid transfection reagent is selected from the group consisting of from the group consisting of Xfect™ transfection reagent, Lipofectamine™ LTX transfection reagent, Lipofectamine 2000™ transfection reagent, SiQuest™ transfection reagent, Transit-siQuest™ transfection reagent, Transit-TKO™ transfection reagent, Transit-LTI™ transfection reagent, Transit-Jurkat™ transfection reagent, Transit-2020™ transfection reagent; chloroquine, PEG, and combinations thereof.

Assignments (2)
CHANGE OF NAME Recorded Aug 4, 2016
From: CLONTECH LABORATORIES, INC.
To: TAKARA BIO USA, INC.
Reel/Frame 039584/0025 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2012
From: BISGROVE, DWAYNE; SAGAWA, HIROAKI
To: CLONTECH LABORATORIES, INC.
Reel/Frame 027880/0817 →